☰
Skip to content
Home
Studies
BioFINDER One
BioFINDER Two
BioFINDER Sleep
BioFINDER Preclinical AD
BioFINDER Primary Care
BioFINDER Memory Clinic
Study Group
Publications
News
Deltagare / Participants
Effects of time of the day at sampling on CSF and plasma levels of Alzheimer’ disease biomarkers
2024
Alzheimers Res Ther. 2024 Jun 22;16(1):132. doi: 10.1186/s13195-024-01503-x.PMID: 38909218 Free PMC article.
Orduña Dolado A, Stomrud E, Ashton NJ, Nilsson J, Quijano-Rubio C, Jethwa A, Brum WS, Brinkmalm Westman A, Zetterberg H, Blennow K, Janelidze S,
Hansson O.
Alzheimers Res Ther. 2024 Jun 22;16(1):132. doi: 10.1186/s13195-024-01503-x.PMID: 38909218
Free PMC article.
2024
Alpha-synuclein seed amplification assay longitudinal outcomes in Lewy body disease spectrum.
2024
Plasma p-tau217 in Alzheimer’s disease: Lumipulse and ALZpath SIMOA head-to-head comparison.
2024
Plasma neurofilament light outperforms glial fibrillary acidic protein in differentiating behavioural variant frontotemporal dementia from primary psychiatric disorders.
2024
Balance and gait disorders in de novo Parkinson’s disease: support for early rehabilitation.
2024
Strong diagnostic performance of plasma ptau217 for CSF biomarker-defined young-onset Alzheimer disease in a diagnostically heterogeneous clinical cohort.
2024
Altered Empathy Processing in Frontotemporal Dementia.
2024
Multiomics profiling of DNA methylation, microRNA, and mRNA in skeletal muscle from monozygotic twin pairs discordant for type 2 diabetes identifies dysregulated genes controlling metabolism.
2024
Corticotropin-releasing hormone as a candidate biomarker for parkinsonian disorders.
2024
Free Recall Outperforms Story Recall in Associations with Plasma Biomarkers in Preclinical Alzheimer Disease.
2024
Diagnosis of Alzheimer’s disease using plasma biomarkers adjusted to clinical probability.
2024
GBA1 T369M and Parkinson’s disease – Further evidence of a lack of association in the Swedish population.
2024
A comprehensive head-to-head comparison of key plasma phosphorylated tau 217 biomarker tests.
2024
Individualized, cross-validated prediction of future dementia using cognitive assessments in people with mild cognitive symptoms.
2024
Phosphorylated tau in cerebrospinal fluid-derived extracellular vesicles in Alzheimer’s disease: a pilot study
2024
Biological mechanisms of resilience to tau pathology in Alzheimer’s disease.